Kineta Inc. resumes VISTA-101 trial enrollment for KVA12123 in advanced solid tumors
Kineta Inc. has announced the resumption of patient enrollment in its VISTA-101 Phase 1/2 clinical trial, which is evaluating the efficacy of KVA12123 in treating advanced solid tumors. This decision follows a significant agreement with TuHURA Biosciences, Inc., which includes the potential acquisition of Kineta’s KVA12123 VISTA blocking antibody along with associated rights and assets. […]